Update after half-year results
In a well-received announcement that complied with the recent Swiss restrictions on commentary in business updates, Kinarus has reported its financial results to the end of June 2023. We address that report and provide some additional narrative on what we assume are the many moving parts and corporate activity behind the scenes.For the six months to 30 June 2023, Kinarus’s R&D expense increased slightly to CHF 272k from CHF 236k for the corresponding H1 2022 and which were attributable to the ongoing Phase 2 KINFAST of KIN001 study in ambulatory COVID-19 patients and patent maintenance costs.
Cash at the end of June 2023 was CHF 150k (vs. CHF 1.3m at the end of FY2022) and we would expect costs to naturally reduce as the KINFAST study completes and cash is conserved prior to partnering.
We have not updated our forecasts for FY 2023 because of the many variables in play at Kinarus. Kinarus has supportive shareholders that are bridge-financing the company to the CHF1.5m transaction by ChaoDian (Hangzhou) Investment Management (CDIM) which facilitates the licensing of its lead drug, KIN001 for idiopathic pulmonary fibrosis (IPF) in China.
While we await the completion of the CDIM and subsequent transactions, our fair value for Kinarus remains at CHF 93m, or CHF 0.093 per share.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.